CTNM

Contineum Therapeutics Stock Analysis

AI Rating

Good
  • Quality3/10
  • Growth↓ 4/10
  • Value↑ 5/10
Contineum Therapeutics sales and earnings growth
CTNM Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ 1.52%
  • FCF Y/Y↓ -45.33%
Contineum Therapeutics gross and profit margin trends
CTNM Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Contineum Therapeutics net debt vs free cash flow
CTNM Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Contineum Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks